Aim Mouse models have indicated that the pneumococcal polysaccharide vaccine (PPV)
can reduce atherosclerosis. This is probably through a process of molecular mimicry, where …

Background and aims Observational studies have demonstrated that the pneumococcal
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …

Background The pneumococcal polysaccharide vaccine (PPV) has been associated with
reduced risk of cardiovascular events in human observational studies. Animal studies …

Background Research has shown that vaccination with Streptococcus pneumoniae reduced
the extent of atherosclerosis in experimental animal models. It is thought that …

Animal models and clinical studies suggest a mechanistic link between the pneumococcal
polysaccharide vaccine (PPV) and a cardiovascular protective effect. However, conflicting …

The UK has had a pneumococcal polysaccharide vaccination (PPV) programme for groups
at higher risk of invasive disease since 1992. This paper presents data from a sample of …

Objective There is evidence that the pneumococcal polysaccharide vaccine (PPV) may
reduce cardiovascular disease. We aimed to evaluate the cost-effectiveness of PPV for …

Background Pneumococcal disease in older adults in the United Kingdom is rising despite
immunisation. A key gap in the literature is the clinical effectiveness of revaccination with the …

Background In the UK certain groups with pre-disposing conditions are eligible for
vaccination with the pneumococcal polysaccharide vaccine (PPV23). Uptake of the vaccine …

Over the past decades there has been an ongoing debate whether preventing lower
respiratory tract infections through pneumococcal (polysaccharide) vaccination (PPV) could …